Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(9%)
Results Posted
100%(8 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
5
45%
Ph phase_1
2
18%
Ph phase_2
3
27%

Phase Distribution

2

Early Stage

3

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
3(30.0%)
Phase 3Large-scale testing
5(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

1

trials recruiting

Total Trials

11

all time

Status Distribution
Active(2)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Terminated1
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
1
Success Rate
88.9%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 23 (30.0%)
Phase 35 (50.0%)

Trials by Status

terminated19%
not_yet_recruiting19%
recruiting19%
completed873%

Recent Activity

Clinical Trials (11)

Showing 11 of 11 trials
NCT06987383Phase 3

Vibegron for ENergy Thinking and Resilience in Aging

Not Yet Recruiting
NCT05067478

Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)

Completed
NCT04103450Phase 3

Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia

Completed
NCT03902080Phase 3

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Completed
NCT05491525Phase 2

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC

Recruiting
NCT03806127Phase 2

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome

Completed
NCT03583372Phase 3

An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).

Completed
NCT03492281Phase 3

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Completed
NCT01314872Phase 2

A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)

Completed
NCT01500382Phase 1

A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)

Terminated
NCT01737684Phase 1

A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11